Satellos Bioscience Inc.
MSCLF
$0.4284
$0.01934.72%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 14.95M | 14.25M | 14.11M | 12.79M | 12.44M |
| Gross Profit | -14.95M | -14.25M | -14.11M | -12.79M | -12.44M |
| SG&A Expenses | 6.82M | 6.21M | 6.00M | 6.32M | 6.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.14M | 20.66M | 20.31M | 19.32M | 18.96M |
| Operating Income | -22.14M | -20.66M | -20.31M | -19.32M | -18.96M |
| Income Before Tax | -22.65M | -21.50M | -20.55M | -20.99M | -17.02M |
| Income Tax Expenses | 95.00K | 63.00K | -- | -- | -- |
| Earnings from Continuing Operations | -22.74 | -21.56 | -20.55 | -20.99 | -17.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.74M | -21.56M | -20.55M | -20.99M | -17.02M |
| EBIT | -22.14M | -20.66M | -20.31M | -19.32M | -18.96M |
| EBITDA | -22.13M | -20.65M | -20.30M | -19.32M | -18.95M |
| EPS Basic | -0.16 | -0.17 | -0.18 | -0.19 | -0.15 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.10 | -0.10 | -0.09 |
| EPS Diluted | -0.16 | -0.17 | -0.18 | -0.19 | -0.15 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.10 | -0.10 | -0.09 |
| Average Basic Shares Outstanding | 570.58M | 512.15M | 459.11M | 451.41M | 451.17M |
| Average Diluted Shares Outstanding | 570.58M | 512.15M | 459.11M | 451.41M | 451.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |